Efficacy and safety of the fixed combination Timolol 0,5%/Travoprost 0,004% compared the concomitant administration to the single components.

Effect of the fixed versus unfixed combination of timolol and travoprost on intraocular pressure in 40 Caucasian patients with primary open angle glaucoma or ocular hypertension in 6 months follow up period.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12612000247875

Enrollment

Registered

2012-02-28

Start date

2011-02-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The aim of our research was to assess the safety and efficacy of changing antiglaucoma therapy to the timolol 0,5% / travoprost 0,004% fixed combination administered once daily, from previous monotherapies, in a group of 40 patients with open-angle glaucoma followed for a period of six months.The combination was a valid defense in the treatment of open angle glaucoma

Interventions

Use of timolol and travoprost in treatment of primary open angle glaucoma. Arm 1-Timolol 0,5% twice daily was instilled for 30 days in 80 eyes Arm 2- Timolol 0,5% twice daily and travoprost 0,004% once a day were instilled for 30 days. Arm 3- Fixed combination of timolol 0,5% /travoprost 0,004% once a day were instilled for 30 days. The mode of instillation of these treatments is self-administration

Study design

Allocation

Non-randomised trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients over 18 years with clinical diagnosis of primary open angle glaucoma or ocular hypertension who had been treated with any therapy

Exclusion criteria

Abnormal corneal sensation, condition preventing tonometry, ocular opacity or insufficient dilation preventing retinal evaluation, narrow anterior chamber angle, inflammatory ocular surface disease, anterior/posterior uveitis, ocular inflammation/infection, progressive retinal disease, significant ocular signs/symptoms, allergic conjunctivitis, significant visual field defect or progressive visual field loss within the last year, history of certain ocular surgeries, significant cardiovascular disease, and history of pulmonary disease including asthma.

Outcome results